ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models

Delta-like-ligand 4 (DLL4) is a promising target to augment the effects of VEGF inhibitors. A simultaneous blockade of VEGF/VEGFR and DLL4/Notch signaling pathways leads to more potent anti-cancer effects by synergistic anti-angiogenic mechanisms in xenograft models. A bispecific antibody targeting...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeom, Dong-Hoon, Lee, Yo-Seob, Ryu, Ilhwan, Lee, Sunju, Sung, Byungje, Lee, Han-Byul, Kim, Dongin, Ahn, Jin-Hyung, Ha, Eunsin, Choi, Yong-Soo, Lee, Sang Hoon, You, Weon-Kyoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796106/
https://www.ncbi.nlm.nih.gov/pubmed/33383646
http://dx.doi.org/10.3390/ijms22010241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796106/
https://www.ncbi.nlm.nih.gov/pubmed/33383646
http://dx.doi.org/10.3390/ijms22010241

Ejemplares similares